| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure +1 more
Section 1. Registered Office. The registered office of Olema Oncology, Inc. (the “Corporation”) in the State of Delaware shall as set forth in the certificate of incorporation of the Corporation, as the same may be amended or restated fr... |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 |
| 15 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective October 14, 2026. Dr. Hrustanovic also resigned fro... |
| 13 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Olema Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment as its Chief Financial Officer, pursuant to the terms of this offer letter agreement (the “Agreement”). |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Olema Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of ... |
| 26 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer |
| 21 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients |
| 01 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On April 27, 2026, Olema Pharmaceuticals, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with KR Oyster Point II, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease an ... |
| 29 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN FRANCISCO, April 29, 2026 (GlobeNewswire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted ... |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer |
| 30 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter sets forth the terms of the separation and consulting agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing medicines for breast cancer and beyond Corporate Overview January 2025 |
| 19 Nov 2025 |
8-K: Other Events
Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”... |
| 18 Nov 2025 |
8-K: Other Events
Effective November 18, 2025, the Company terminated the prospectus (the “ATM Prospectus”) related to the sale of its common stock, $0.0001 par value per share (the “Common Stock”) in an “at-the-market” offering pursuant to the terms of t... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer |
| 20 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Advancing medicines for breast cancer and beyond Corporate Overview October 2025 |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing medicines for breast cancer and beyond Corporate Overview August 2025 |
Loading...